Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Do Drivers Interact with In-Vehicle Well-being Interventions? An Exploratory Analysis of a Longitudinal Study on Public Roads.

Proceedings of the ACM on interactive, mobile, wearable and ubiquitous technologies·2022
Same author

Intensity of Treatment as Usual and Its Impact on the Effects of Face-to-Face and Internet-Based Psychotherapy for Depression: A Preregistered Meta-Analysis of Randomized Controlled Trials.

Psychotherapy and psychosomatics·2022
Same author

Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.

Wiener medizinische Wochenschrift (1946)·2022
Same author

Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease.

Orphanet journal of rare diseases·2022
Same author

Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score.

Frontiers in neurology·2022
Same author

Diagnostic Approach and Treatment Regimens in Adult Patients Suffering from Antibody- mediated or Paraneoplastic Encephalitis.

Current pharmaceutical design·2022
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Current therapeutic recommendations in multiple sclerosis.

Thomas Berger1

  • 1Neuroimmunological and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. thomas.berger@i-med.ac.at

Journal of the Neurological Sciences
|January 29, 2010
PubMed
Summary
This summary is machine-generated.

Early immunotherapy for multiple sclerosis (MS) is crucial due to ongoing inflammation. Treatment effectiveness requires careful monitoring, with escalation therapy reserved for aggressive disease cases. Keywords: multiple sclerosis, immunotherapy, glatiramer acetate, interferon-beta, natalizumab, MRI monitoring, escalation therapy.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jun 16, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neurology
  • Immunology
  • Clinical Medicine

Background:

  • Recent clinical studies offer new insights into glatiramer acetate, interferon-beta, and natalizumab for multiple sclerosis (MS).
  • Continuous inflammatory disease activity necessitates prompt immunotherapy initiation post-diagnosis.
  • Glatiramer acetate recently gained approval for clinically isolated syndrome, expanding early treatment options.

Purpose of the Study:

  • To review current data on MS immunotherapies and their impact on patient care optimization.
  • To discuss the criteria for evaluating treatment response and failure in MS patients.
  • To define parameters for escalation therapy in aggressive MS cases.

Main Methods:

  • Review of recent clinical studies and data on MS therapies.
  • Analysis of diagnostic and monitoring strategies, including MRI.
  • Evaluation of treatment response and escalation criteria.

Main Results:

  • Early immunotherapy is recommended for MS due to persistent inflammation.
  • Frequent MRI monitoring utility and limitations require further clarification.
  • Treatment failure indicators include relapses, disability progression, or MRI evidence of disease activity.

Conclusions:

  • Optimizing MS patient care involves timely immunotherapy and careful treatment monitoring.
  • Clear definitions for treatment failure and escalation are needed, considering clinical and MRI data limitations.
  • Escalation therapy is indicated for aggressive MS, defined by specific relapse and progression criteria.